Advertisement

Letter re: “Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review and Bayesian network meta-analysis”

  • Alessandro Rizzo
    Correspondence
    Corresponding author: Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II,", Viale Orazio Flacco 65, Bari, 70124, Italy. Fax: +39 051-6364037
    Affiliations
    Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II," Viale Orazio Flacco 65, Bari, 70124, Italy
    Search for articles by this author
  • Giovanni Brandi
    Affiliations
    Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Via Giuseppe Massarenti, 9, 40138 Bologna, Italy

    Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni, 15, 40138 Bologna, Italy
    Search for articles by this author
      The cardiotoxicity of anticancer drugs represents a long-standing, important, and widely discussed issue in medical oncology [
      • Omland T.
      • Heck S.L.
      • Gulati G.
      The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review.
      ]. We have witnessed impressive advances in cancer management over the last decade, with novel treatments reporting unprecedented response rates and improving clinical outcomes in several haematological and solid tumours [
      • Livi L.
      • Barletta G.
      • Martella F.
      • Saieva C.
      • Desideri I.
      • Bacci C.
      • et al.
      Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial.
      ]. Nonetheless, if on the one hand, new therapies have showed superior efficacy; on the other hand, these treatments have been associated with a non-negligible risk of increased cardiac toxicities. Several types of cardiovascular toxicities have been classically associated to anticancer therapies, including QT prolongation, coronary heart disease, systemic hypertension, myocardial infarction, heart failure, and myocarditis. However, different classes of anticancer drugs have shown a distinct safety profile in terms of cardiovascular toxicities, also inducing cardiotoxicity through different mechanisms. Based on these premises, prompt identification of treatment-related cardiotoxicity and the role of cardioprotective therapies remain timely topics in this setting.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Omland T.
        • Heck S.L.
        • Gulati G.
        The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review.
        JACC CardioOncol. 2022 Mar 15; 4 (. PMID: 35492815; PMCID: PMC9040117): 19-37https://doi.org/10.1016/j.jaccao.2022.01.101
        • Livi L.
        • Barletta G.
        • Martella F.
        • Saieva C.
        • Desideri I.
        • Bacci C.
        • et al.
        Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial.
        JAMA Oncol. 2021 Oct 1; 7 (. PMID: 34436523; PMCID: PMC8391772): 1544-1549https://doi.org/10.1001/jamaoncol.2021.3395
        • Sayed A.
        • Abdelfattah O.M.
        • Munir M.
        • Shazly O.
        • Awad A.K.
        • Ghaith H.S.
        • et al.
        Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: a systematic review & bayesian network meta-analysis.
        Eur J Cancer. 2022 May 4; 169 (Epub ahead of print. PMID: 35524992): 82-92https://doi.org/10.1016/j.ejca.2022.03.024
        • Higgins J.P.
        • Jackson D.
        • Barrett J.K.
        • Lu G.
        • Ades A.E.
        • White I.R.
        Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies.
        Res Synth Methods. 2012 Jun; 3: 98-110
        • Rouse B.
        • Chaimani A.
        • Li T.
        Network meta-analysis: an introduction for clinicians.
        Intern Emerg Med. 2017 Feb; 12 (Epub 2016 Dec 2. PMID: 27913917; PMCID: PMC5247317): 103-111https://doi.org/10.1007/s11739-016-1583-7

      Linked Article